Metagenomi, Inc. (NASDAQ:MGX - Get Free Report) was the recipient of a large drop in short interest in the month of May. As of May 15th, there was short interest totalling 2,400,000 shares, a drop of 18.9% from the April 30th total of 2,960,000 shares. Approximately 11.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 370,900 shares, the short-interest ratio is currently 6.5 days.
Metagenomi Stock Down 4.0%
Metagenomi stock traded down $0.07 during mid-day trading on Wednesday, hitting $1.70. The company's stock had a trading volume of 357,119 shares, compared to its average volume of 790,985. The stock has a market capitalization of $63.55 million, a P/E ratio of -0.81 and a beta of -0.33. Metagenomi has a twelve month low of $1.23 and a twelve month high of $6.90. The stock's fifty day moving average price is $1.57 and its two-hundred day moving average price is $2.24.
Metagenomi (NASDAQ:MGX - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.06). Metagenomi had a negative return on equity of 43.23% and a negative net margin of 134.27%. The company had revenue of $4.13 million during the quarter, compared to analyst estimates of $8.75 million. Equities analysts expect that Metagenomi will post -2.46 earnings per share for the current year.
Analysts Set New Price Targets
Several equities research analysts recently commented on the company. HC Wainwright dropped their target price on Metagenomi from $14.00 to $7.00 and set a "buy" rating on the stock in a report on Thursday, April 3rd. Chardan Capital lowered their price target on Metagenomi from $13.00 to $12.00 and set a "buy" rating on the stock in a research report on Thursday, May 15th. Wall Street Zen lowered Metagenomi from a "hold" rating to a "strong sell" rating in a report on Thursday, May 22nd. Finally, Wells Fargo & Company reaffirmed an "overweight" rating and set a $16.00 target price (down previously from $20.00) on shares of Metagenomi in a research note on Wednesday, May 14th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $13.00.
Get Our Latest Stock Analysis on Metagenomi
Hedge Funds Weigh In On Metagenomi
A number of institutional investors have recently bought and sold shares of MGX. Rhumbline Advisers boosted its holdings in shares of Metagenomi by 123.3% in the fourth quarter. Rhumbline Advisers now owns 11,998 shares of the company's stock worth $43,000 after buying an additional 6,626 shares during the period. Corebridge Financial Inc. lifted its position in shares of Metagenomi by 303.1% in the 4th quarter. Corebridge Financial Inc. now owns 13,602 shares of the company's stock valued at $49,000 after acquiring an additional 10,228 shares in the last quarter. Voya Investment Management LLC acquired a new position in Metagenomi in the 4th quarter worth approximately $37,000. Price T Rowe Associates Inc. MD purchased a new position in Metagenomi during the 4th quarter worth approximately $39,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Metagenomi by 338.7% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,193 shares of the company's stock valued at $55,000 after purchasing an additional 11,730 shares during the period.
Metagenomi Company Profile
(
Get Free Report)
Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.
Featured Articles
Before you consider Metagenomi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metagenomi wasn't on the list.
While Metagenomi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.